Stem cells, an expanding market with vast potential – explore developments and commercial prospects
What does the future hold for that cellular technology? What progress and sales are possible? There avoid struggles to gain business data. Instead find the best places for expanding revenues, also understanding trends, technologies, therapies and opportunities.
Visiongain’s new investigation gives you revenue forecasts to 2025 for the world stem cells market, submarkets and leading products. Avoid missing out. There see what’s happening for those cell-based technologies and uses, discovering the most lucrative applications.
See what gains are possible. Please read on, then, to explore that industry and discover what its future market could be worth.
Forecasts and other analyses showing opportunities in those cellular technologies
Besides revenue forecasting to 2025, our analyses show recent results, growth rates and market shares. There you find original analysis. Also that work lets you assess research and development. And there gain 55 tables, 38 charts and six interviews with organisations.
Now make your searching for data on stem cells easier. Also save time. And benefit your insight and authority. Our study’s purpose is to help in research, analysis and decisions, helping you discover where developments and money lie, staying ahead in knowledge.
And the following sections highlight what’s in that technology, industry and market survey.
Prospects for the overall world market and segments – what’s possible?
What’re the secrets of that industry’s progress? Along with our prediction of the overall world market value for stem cells, our work shows you individual revenue forecasting of five submarkets to 2025 at world level, with discussions:
• Cancer (oncology)
• Central nervous system (CNS) disorders
• Cardiovascular diseases
• Other medical treatments
• Non-therapeutic uses.
Which segment can achieve highest sales? Which has fastest predicted growth? See how and why those commercial uses in healthcare can develop, prosper and gain in importance.
For developers, producers and sellers, assess how those tools, systems and applications earn money. And gauge their potential success from this decade onwards.
Products – discover sales forecasting of leading agents
Our study also shows you individual revenue predictions to 2025 for six top brands:
• Prochymal (Mesoblast)
• Hearticellgram-AMI (Pharmicell)
• CardioRel (Reliance Life Sciences)
• Osteocel Plus (NuVasive)
• Trinity Elite and Evolution (Orthofix)
• Cartistem (Medipost).
There you discover prospects for established and emerging technology and medicines. That market will grow through the approval and launch of many products from this decade.
Our study explains, looking ahead, discussing issues to help your work.
Developments, challenges and opportunities affecting researchers, producers and users
Our investigation lets you assess trends, R&D and outlooks for stem cell technology. There you find discussions of forces, progress and potential:
• Developments in the US, Japan, Europe, South Korea, China, India and Israel, with regulations, achievements, regional prominence and outlooks
• Activities of Mesoblast, Pharmicell, NuVasive, Orthofix, Medipost, Advanced Cell Technology, Athersys, Novartis, GSK and other organisations, private and public
• Approvals of therapies and other products to expand and advance that industry
• Japan’s accelerated marketing authorisation for promising treatments
• Regenerative medicine and uses in diabetes, liver degeneration, Crohn’s disease, diabetes, rheumatoid arthritis and other medical conditions.
That study discusses other influences, including these:
• Embryonic stem cells (ESCs), induced pluripotent adult (IPSCs) and parthenogenetic cells
• Autologous versus allogeneic cellular agents – possibility for universal products
• Haematopoietic stem cell transplantation (HSCT)
• Uses for umbilical cord blood and related technologies, including cellular banking
• Treatments for orphan diseases and difficult-to-cure disorders
• Agents for osteogenesis and treating autoimmune conditions
• Applications in cell-based assays, diagnostics and drug development.
There you explore political, economic, social and technological questions, assessing advances and prospects. You also gain regulatory insights. That way you investigate what helps and restrains those developers, producers and marketers.
Discover there what the past, present and future hold.
Stem cells – what’s next, and world 2018 market value?
From 2014 those technologies, services and products hold great potential for advances, investments and sales. Our work predicts the overall market for stem cells will reach $12bn in 2018, achieving high revenue growth from 2015 to 2025.
That study’s author said: “Therapies in myocardial infarction, heart failure and other prominent diseases have reached phase III trials, suggesting the stem cells market will achieve rapid growth during the middle of our forecast period.
“Clinical-stage companies there focus on CNS disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease. They also tackle ophthalmic conditions, including age-related macular degeneration (AMD).”
Prospects for those medical systems and tools are strong, and from 2015 there will arise many opportunities. Our work shows you the possibilities, helping you stay ahead.
Stem Cell Technologies and Applications: World Industry and Market Outlook 2015-2025 shows information found nowhere else
In particular you gain these analyses to help your research, assessments and decisions:
• Overall world revenue to 2025 – see the results and sales potential of that industry
• Five submarkets’ revenues to 2025 – investigate segments at world level, finding the most lucrative applications
• Six product revenues to 2025 – discover sales predictions for top medical agents, seeing how they can succeed, including what helps and limits their performance
• R&D on stem cells – investigate progress, finding technological, clinical and commercial outlooks, including products expected in the next 10 years
• Activities of established, rising and emerging companies – hear about firms’ capabilities, portfolios, advances and prospects
• Interviews with six organisations – explore views to help your work, getting feel for that sector and its participants
• Analysis of what stimulates and restrains that industry and market – assess challenges and strengths, helping you compete and gain advantages.
Potential for stem cells – discover now what’s possible worldwide from 2015
There you receive business intelligence found only in our work, discovering where money, progress and opportunities lie. That way you can benefit your influence and reputation for insight.
With our new study you’re less likely to miss opportunity or fall behind. Instead stay ahead for knowledge. You explore trends, R&D and sales predications, with discussions. So please get our report here now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Stem Cell Technologies and Applications Market Overview
1.2 Global Stem Cell Technologies and Applications Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Stem Cell Technologies and Applications
2.1 What are Stem Cells?
2.2 Timeline of Stem Cell Research
2.2.1 Embryonic Stem Cells (ESCs) Enter the Picture
2.3 Classifying Stem Cells by Potency
2.3.1 Stem Cell Categories: ESCs, SSCs, IPSCs
2.3.2 Parthenogenetic Stem Cells: Ethical ESC-Like Cells?
2.3.3 Autologous versus Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.3.4 Advantages and Disadvantages of Different Cell Types
2.4 Regulation of Stem Cell Research
2.4.1 Regulation in the US
2.4.1.1 Understanding ‘Homologous Use’
2.4.1.2 Embryonic Stem Cell Research Remains Controversial
2.4.1.3 FDA v Regenerative Sciences: Regulating MSC Therapy
2.4.2 Regulation in Europe
2.4.2.1 The Brüstle Ruling: Dead and Buried?
2.4.2.2 The UK Leads in European Stem Cell R&D
2.4.3 Regulation in Japan
2.4.4 Regulation in Other Regions
2.4.4.1 South Korea Paves a Path for MSC Therapies
2.4.4.2 Liberal Chinese Laws for Stem Cell Research
2.4.4.3 Israel: A Strong Presence in Stem Cell Research
2.4.4.4 India: An Emerging Stem Cell Industry
2.5 Phases of Clinical Trials
2.6 Scope of this Report
2.7 Currency Exchange Rates in This Report
3. Stem Cell Technologies and Applications: World Market 2015-2025
3.1 The World Stem Cell Technologies and Applications Market in 2014
3.2 World Stem Cell Technologies and Applications Market: Regional Breakdown, 2014
3.3 Stem Cell Technologies and Applications Market Segmentation, 2014
3.4 Stem Cell Technologies and Applications Market: Sales Forecast 2015-2025
3.5 Stem Cell Technologies and Applications Market: Sales Forecast by Segment, 2015-2025
3.6 How Will Segmental Market Shares Change to 2025?
3.7 Non-Therapeutic Applications Lead the Stem Cell Technologies and Applications Market
3.8 Stem Cell Technologies and Applications Market: Drivers and Restraints 2015-2025
3.9 Recent Developments
3.9.1 STAP Cell Scandal in Japan
3.9.2 Tracheal Transplant Patient Dies
3.9.3 Stem Cell Rush in Japan after Regulatory Changes?
4. Stem Cell Cancer Therapeutics Segment 2015-2025
4.1 Stem Cell Cancer Therapeutics: Overview
4.2 The Stem Cell Cancer Therapeutics Market in 2014
4.3 Stem Cell Cancer Therapeutics: Market Forecast 2015-2025
4.4 Haematopoietic Stem Cell Transplantation (HSCT)
4.4.1 An Established Treatment for Haematological Cancers
4.4.2 Autologous HSCT Continues to Dominate
4.4.3 Allogeneic HSCT: More Rejections, Fewer Relapses
4.4.4 GvHD: The Major Issue for HSCT
4.4.5 Peripheral Blood: More Anti-Tumour Effect, More GvHD Risk
4.4.6 The Rise of Umbilical Cord Blood
4.4.7 80,000 HSCT Operations Performed Worldwide in 2014
4.4.8 HSCT Costly, Medicare Coverage Selective
4.4.9 Haematological Malignancies are the Major Indication for HSCT
4.4.10 HSCT Addresses Cancers Representing a $20bn Market
4.5 From Procedures to Products: Cord Blood Stem Cell Approvals
4.5.1 Hemacord (New York Blood Center)
4.5.2 HPC, Cord Blood (ClinImmune/University of Colorado Cord Blood Bank)
4.5.3 Ducord (Duke University School of Medicine)
4.5.4 Allocord (SSM Cardinal Glennon Children’s Medical Center)
4.5.5 HPC, Cord Blood BLA 125432 (LifeSouth Community Blood Centers)
4.6 Stem Cell Cancer Therapeutics: Pipeline Review 2015-2025
4.6.1 Apceth: Genetically Modified MSCs for Gastrointestinal Cancer
4.6.2 Athersys: MultiStem in Haematological Malignancies
4.6.3 Cellerant Therapeutics: CLT-008 and CLT-009
4.6.4 Cynata Therapeutics: Mass Producing MSCs for GvHD?
4.6.5 Fate Therapeutics: Modified HSCs for Haematological Malignancy
4.6.6 Gamida Cell: Shifting Focus from StemEx to NiCord
4.6.6.1 Survival at 100 Days Improved by StemEx in Latest Trial
4.6.6.2 NiCord Heads Up a Pipeline of Novel Cell Therapies
4.6.6.3 Novartis in Talks to Acquire Gamida Cell
4.6.7 ImmunoCellular Therapeutics: Stem Cells for Cancer Immunotherapy
4.6.8 Mesoblast: Using Mesenchymal Precursors to Enrich Cord Blood
4.6.8.1 Prochymal (remestemcel-L/MSC-100-IV, Mesoblast): Limited Market Access
4.6.8.2 The Development of Prochymal
4.6.8.3 Success in Subsets of GvHD Patients
4.6.8.4 An Important Role to Play in the Future of HSCT
4.6.8.5 Prochymal: Sales Forecast 2015-2025
4.6.8.6 Phase 3 Trial in Haematological Malignancies
4.6.8.7 A Competitor for Gamida Cell?
4.6.9 Novartis Developing Cord Blood Transplant Candidates
4.6.9.1 HSC835 Expanding Umbilical Cord Blood
4.6.9.2 Novartis Partners with Regenerex for Cell-Based Therapies
4.7 Other Stem Cell Oncology Prospects
4.7.1 Ancillary Products for the HSCT Setting
4.7.2 Targeting Cancer Stem Cells (CSCs)
4.7.3 Immunovative Therapies: Building on HSCT for a Cellular Anti-Cancer Therapy
4.8 Stem Cell Cancer Therapeutics: Drivers and Restraints 2015-2025
5. Stem Cell Cardiovascular Therapeutics Segment 2015-2025
5.1 Stem Cell Cardiovascular Therapeutics: Overview
5.2 The Stem Cell Cardiovascular Therapeutics Market in 2014
5.3 Stem Cell Cardiovascular Therapeutics: Market Forecast 2015-2025
5.4 Cardiovascular Diseases Dominate the Global Pharmaceutical Market
5.4.1 Cardiovascular and Cerebrovascular Conditions Are the World’s Most Fatal Diseases
5.4.2 AMI, CLI and Stroke: Major Ischaemic Disease Targets
5.5 The State of Stem Cell Research for Cardiovascular Diseases
5.5.1 Can Stem Cells Heal the Heart and Vasculature?
5.5.2 Stem Cell Treatments for Stroke
5.5.3 Defining Cardiovascular Stem Cells
5.6 Safety and Efficacy of MSCs in Clinical Trials
5.6.1 The Mysterious Efficacy of Adult Stem Cells in the Heart
5.6.2 Therapeutic Effects Despite Rapid Clearance
5.6.3 Doubts over the Efficacy of MSCs in the Heart
5.6.4 Looking Beyond MSCs
5.7 Stem Cell Cardiovascular Therapeutics in the Market
5.7.1 Pharmicell: Hearticellgram-AMI, One of the First Approved Cardiovascular Stem Cell Treatments
5.7.1.1 Hearticellgram-AMI Sales 2012-2013
5.7.1.2 Difficulty Accessing Markets Outside South Korea
5.7.1.3 Hearticellgram-AMI: Sales Forecast 2015-2025
5.7.1.4 Pharmicell: Pipeline Products
5.7.2 Reliance Life Sciences: CardioRel
5.8 Stem Cell Cardiovascular Therapeutics: Pipeline Review 2015-2025
5.8.1 Cytomedix Rebrands as Nuo Therapeutics, Exits Stem Cell R&D
5.8.2 Aastrom Biosciences (Vericel Corporation): Ixmyelocel-T
5.8.2.1 New Focus on Dilated Cardiomyopathy
5.8.3 Apceth: MSCs for Advanced Peripheral Vascular Disease
5.8.4 Arteriocyte: Nanex Technology to Treat CLI
5.8.5 Athersys: MultiStem in Stroke and Acute Myocardial Infarction
5.8.6 Baxter: Phase 3 in Refractory Angina
5.8.7 BioCardia: MSC Therapies for Heart Failure and AMI
5.8.8 Biogenea-Cellgenea: Still Developing Cardiogenea?
5.8.9 Bioheart: Phase 3 in Heart Failure, But Needs Extra Funding
5.8.9.1 Seeking Expanded Access for Compassionate Use
5.8.10 Capricor: Cardiosphere-Derived Cells for Heart Repair
5.8.11 Cardio3 BioSciences: Cardiopoiesis for Heart Regeneration
5.8.11.1 Phase 3 Trial Begins Amid Controversy
5.8.12 CellProthera: Myocardial Tissue Regeneration
5.8.13 Cytori Therapeutics: Stem Cells for Acute Myocardial Infarction
5.8.14 Human Stem Cells Institute: Developing Gemacell and Cryocell
5.8.15 Mesoblast: Mesenchymal Precursor Cells for Heart Failure and Myocardial Infarction
5.8.15.1 CEP-41750 Moving to Phase 3 in Congestive Heart Failure
5.8.15.2 Phase 2 in Acute Myocardial Infarction
5.8.15.3 Promising Preclinical Findings in Ischaemic Stroke
5.8.15.4 Teva Collaborating on Cardiovascular Stem Cell Therapy R&D
5.8.16 NeoStem: Diversified Outfit with One of the Leading Candidates
5.8.16.1 NBS10 to Treat Acute Myocardial Infarction
5.8.17 Stemedica Cell Technologies: Ischaemic-Tolerant Stem Cell Platform
5.8.17.1 Phase 2 in Acute Myocardial Infarction, Ischaemic Stroke, Heart Failure and Cutaneous Photoaging
5.8.18 Stempeutics: Emerging Indian Company Targets CLI
5.8.19 Other Stem Cell Cardiovascular Prospects
5.9 Can Stem Cells Change The Treatment Paradigm for Cardiovascular Disease?
6. Stem Cell Central Nervous System Therapeutics Segment 2015-2025
6.1 Stem Cell Central Nervous System Therapeutics: Overview
6.2 The Stem Cell Central Nervous System Therapeutics Market in 2014
6.3 Stem Cell Central Nervous System Therapeutics: Market Forecast 2015-2025
6.4 The State of Stem Cell Research in CNS Diseases
6.4.1 Stem Cells the Best Hope for Many Serious CNS Conditions
6.4.2 Awaiting a First Breakthrough Approval
6.4.3 Human NSCs Successfully Isolated
6.4.4 NSCs Reach the Clinic
6.4.5 CNS Disorders are the Major Focus for ESC Research
6.4.6 MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
6.5 Progress in Specific CNS Conditions
6.5.1 HSCT in MS: Could ‘Resetting’ the Immune System Treat MS?
6.5.2 ALS: Rare Disease Could be the First Neurodegenerative Condition for Stem Cell Treatment
6.5.3 Parkinson’s Disease: Moratorium on Stem Cell Research Ends
6.5.4 Dry Age-Related Macular Degeneration: A Major Unmet Need
6.5.5 Several Multi-Billion Dollar Potential Markets in the Sights of CNS Stem Cell Developers
6.6 Stem Cell Central Nervous System Therapeutics: Pipeline Review 2015-2025
6.6.1 Advanced Cell Technology: Stem Cells for Eye Diseases
6.6.1.1 Stargardt’s Macular Degeneration: Moving to Phase 2
6.6.1.2 Early Signals of Efficacy, or Confounded Results?
6.6.1.3 Advancing to Phase 2 in Dry AMD
6.6.2 Athersys: Multistem for Ischaemic Stroke
6.6.3 BrainStorm Cell Therapeutics: Neurotrophic Factor-Releasing Stem Cells for ALS
6.6.3.1 Phase 2 Trial in 48 ALS Patients Underway
6.6.4 Cellonis Biotechnologies: Switching From Diabetes to Stroke
6.6.5 Corestem: MSCs for ALS
6.6.6 International Stem Cell Corporation: Preclinical CNS Treatments
6.6.7 InVivo Therapeutics: Neuro-Spinal Scaffold for Spinal Cord Injury
6.6.8 Mesoblast: Phase 2 in Wet AMD, Preclinical in Neurology
6.6.9Neuralstem: Allogeneic Neural Stem Cells for Synaptic Repair and Neuroprotection
6.6.9.1 Long-Term Follow-Up Data is Promising in ALS
6.6.9.2 Chronic and Acute Spinal Cord Injury Treatment to Follow
6.6.9.3 Ischaemic Stroke: Phase 1/2 Trials Underway in China
6.6.10 Preclinical Work in Other Neurological Disorders
6.6.11 NeuroGeneration: Investigating Human NSCs
6.6.12 Pfizer: Collaborating on the London Project to Cure Blindness
6.6.13 Q Therapeutics: Glial-Based Stem Cells as an ALS Treatment
6.6.14 ReNeuron: ReN001 is Demonstrating Potential in Stroke
6.6.14.1 Foetally-Sourced Cells Have Wide Potential Application
6.6.15 RhinoCyte: Stem Cells from the Nasal Passage to the Spinal Cord
6.6.16 SanBio: SB623 for Ischaemic Stroke
6.6.16.1 Future SanBio Programmes at Preclinical Stage in 2014
6.6.17 StemCells: a Leader in Neural Stem Cells
6.6.17.1 HuCNS-SC Product Proving Itself in Rare Indications
6.6.17.2 Moving on to Spinal Cord Injury and AMD
6.6.17.3 Alzheimer’s Disease and Stroke to Follow?
6.7 Other Companies with Technologies of Interest
6.7.1 iPierian – Bringing IPSCs to the CNS Market?
6.8 Stem Cell CNS Therapeutics: Drivers and Restraints 2015-2025
7. Stem Cell Therapeutics in Other Disease Areas 2015-2025
7.1 Stem Cell Therapeutics in Other Disease Areas: Overview
7.2 Stem Cell Therapeutics in Other Disease Areas: The Market in 2014
7.3 Stem Cell Therapeutics in Other Disease Areas: Market Forecast 2015-2025
7.4 Stem Cell Therapeutics for Other Diseases in the Market
7.4.1 Osteocel Plus (NuVasive): The Leading Stem-Cell Orthobiologic
7.4.1.1 Osteocel to Osteocel Plus: A Chequered History
7.4.1.2 Better than Autograft?
7.4.1.3 Osteocel Plus: Sales Forecast 2015-2025
7.4.2 Trinity Elite and Evolution (Orthofix): Second-Generation Stem Cell Orthobiologics
7.4.2.1 Trinity Elite and Evolution: Sales Forecast 2015-2025
7.4.3 Cartistem (Medipost): ‘World’s First Allogeneic Stem Cell Drug’
7.4.3.1 Cartistem: Sales Forecast 2015-2025
7.4.4 LiquidGen (Skye Orthobiologics): Liquid Amniotic Allograft
7.4.5 AlloStem (Allosource)
7.4.6 Map3 (RTI Surgical)
7.5 Stem Cell Therapeutics for Other Diseases: Research Areas
7.5.1 HSCT for Orphan Diseases
7.5.2 Genetically Modified Stem Cells for HIV and Other Diseases
7.5.3 Stem Cells Are Osteogenic
7.5.4 Perianal Fistula Treatment Indicates Stem Cells’ Potential in Tissue Repair
7.5.5 Autoimmune Disorders Offer Real Market Potential
7.5.6 A Potential Cure for Diabetes?
7.5.7 Stem Cells in Active Liver Repair
7.5.8 Long-Range Possibilities
7.6 Stem Cell Therapeutics in Other Disease Areas: Pipeline Review 2015-2025
7.6.1 Alliancells Bioscience Corporation: Possible RA Treatment
7.6.2 AlloCure: AC607 Phase 2 Study Terminated
7.6.3 American CryoStem: ATCELL Preclinical Programmes
7.6.4 Anterogen: South Korean Stem Cell Company
7.6.5 Athersys: MultiStem Fails Phase 2 in Ulcerative Colitis
7.6.6 BioRestorative Therapies: Exploring Disc Disease and Diabetes
7.6.7 BioTime: Multiple Subsidiaries, Multiple Therapies
7.6.7.1 Asterias Biotherapeutics: Neurology and Oncology
7.6.7.2 Cell Cure Neurosciences: Phase 1/2a in Dry AMD
7.6.7.3 OncoCyte: Cancer Diagnostics
7.6.7.4 OrthoCyte: Orthopaedic Stem Cell Treatments
7.6.7.5 ReCyte: ESCs and IPSCs for Cardiovascular Diseases
7.6.7.6 Other BioTime Subsidiaries
7.6.8 Calimmune: Dual Anti-HIV Gene Therapy via Stem Cells
7.6.9 Celgene Cellular Therapeutics: Targeting Inflammatory Conditions
7.6.10 Cellular Biomedicine Group: MSCs for Knee Osteoarthritis
7.6.11 IntelliCell BioSciences: Adipose-Derived Stem Cells
7.6.12 Life Stem Genetics: Adipose-Derived Stem Cells
7.6.13 Medipost: Four Programmes in Development
7.6.14 Medistem: Acquired by Intrexon
7.6.15 Medistem Panama: Investigating MSCs
7.6.16 Mesoblast: MPCs for Crohn’s Disease, Diabetes and Rheumatoid Arthritis
7.6.16.1 Prochymal in Crohn’s Disease: Phase 3
7.6.16.2 Allogeneic MPCs for Diabetes in Phase 2
7.6.16.3 Allogeneic MPCs for Rheumatoid Arthritis in Phase 2
7.6.16.4 Allogeneic MPCs in Intervertebral Disc Repair and Spinal Fusion: Phase 2
7.6.17 Pluristem Therapeutics: Placental Stem Cells for Cardiovascular Diseases
7.6.18 Regeneus: Taking Adipose-Derived MSCs into Clinical Trials
7.6.19 S-Evans Biosciences: Menstrual Stem Cells for Hepatic Disease
7.6.20 TiGenix: Expanded Adipose-Derived Stem Cell Therapies
7.6.20.1 Cx601: Phase 3 Data Expected In July 2015
7.6.20.2 Cx611: Phase 2 in Rheumatoid Arthritis
7.6.20.3 Cx621: Intralymphatic Stem Cells for Autoimmune Diseases
7.6.20.4 ChondroCelect Already on the Market
7.6.21 ViaCyte: Revolutionising Diabetes Treatment with VC-01?
7.6.22 ViroMed: Genetically Modified Stem Cells for Chronic Granulomatous Disease
7.7 Genetically Modified Stem Cell Therapy Pipeline
7.7.1 Bluebird Bio: Gene-Modified HSCs for Orphan Diseases
7.7.2 GSK: Ex-Vivo Stem Cell Gene Therapies for Rare Diseases
7.7.3 Sangamo BioSciences: Genetically Modified Stem Cells for HIV
8. Stem Cell Non-Therapeutic Applications 2015-2025
8.1 Stem Cell Non-Therapeutic Applications: Overview
8.2 Stem Cell Non-Therapeutic Applications Market in 2014
8.3 Stem Cell Non-Therapeutic Applications: Market Forecast 2015-2025
8.4 Stem Cell Banking: Growing Demand Worldwide
8.4.1 Dental Stem Cell Banking: An Alternative to Cord Blood Banks?
8.5 Stem Cell Supply and Processing: IPSCs the New Driver
8.6 Stem Cell-Based Assays: Major Potential for Preclinical Screens
8.7 Research, Reagents, and Other Non-Therapeutic Stem Cell Activities
8.8 The Outlook for Non-Therapeutic Stem Cell Activities
9. Qualitative Analysis of the Stem Cell Technologies and Applications Market 2015-2025
9.1 SWOT Analysis of the Stem Cell Technologies and Applications Market
9.2 Strengths
9.2.1 HSCT is an Established Procedure
9.2.2 Recent Approvals of Stem Cell Therapies
9.2.3 Relaxation of Regulatory Barriers
9.3 Weaknesses
9.3.1 Uncertain Mechanism of Action in Stem Cell Therapies
9.3.2 Few Late-Stage Pipeline Products
9.3.3 Regulatory and Reimbursement Concerns
9.4 Opportunities
9.4.1 Genetic Modification of Stem Cells
9.4.2 Unmet Clinical Needs
9.4.3 Non-Therapeutic Uses: Cord Banking and Cell-Based Assays
9.4.4 Interactions with Related Technologies
9.5 Threats
9.5.1 Financial Risks
9.5.2 Pipeline Failure
9.5.3 Long-Term Safety Concerns
9.6 STEP Analysis of the Stem Cell Technologies and Applications Market
9.7 Social Factors
9.7.1 Increasing Burden of Disease
9.7.2 Biological Insurance through Stem Cell Banking
9.7.3 Stem Cell Tourism: the Hype and the Hope
9.8 Technological Factors
9.8.1 Increasing Research Output
9.8.2 IPSC Breakthroughs
9.8.3 Greater Understanding of Stem Cell Differentiation
9.8.4 Biomaterials, Bioprinting and Other Developments
9.8.5 CRISPRs: A Breakthrough in Genome Editing
9.9 Economic Factors
9.9.1 Grey Market for Stem Cell Therapies
9.9.2 Broad Changes in Pharma/Healthcare Markets
9.9.3 The Business Model Needs Further Development
9.10 Political Factors
9.10.1 Ethical Objections to Embryonic Stem Cell Research
9.10.2 Strong Support from National Governments
9.10.3 Pressure to Deregulate the Stem Cell Therapies Market
10. Research Interviews
10.1 Interview with Mr Brock Reeve, Executive Director, Harvard Stem Cell Institute, Massachusetts, US
10.1.1 Recent Developments in Stem Cells
10.1.2 Stem Cell Techniques and Therapies in 2015-2025
10.1.3 Potential Applications of Genome Editing
10.1.4 Therapeutic Areas for Stem Cell Therapies
10.1.5 The Need for New Business Models?
10.1.6 Developing the Stem Cell Therapy Market
10.1.7 Other Trends and Developments
10.2 Interview with Dr Mark Berman, Founder, Cell Surgical Network, US
10.2.1 Cell Surgical Network: Stem Cell Therapies
10.2.2 Cell Therapy as Investigative Treatment
10.2.3 Promising Therapeutic Applications
10.2.4 Future Developments for CSN and Stem Cell Therapies
10.2.5 The Need for New Business Models?
10.2.6 Regulatory Issues in Japan and Elsewhere
10.2.7 The FDA and Cell Surgical Network
10.2.8 Developing the Stem Cell Therapy Market
10.2.9 Other Trends and Developments
10.3 Interview with Dr Leonard Zon, Director of the Stem Cell Program at Children's Hospital Boston, Massachusetts, US
10.3.1 Recent Developments in Stem Cells
10.3.2 Research at Zon Laboratory
10.3.3 Stem Cell Techniques and Therapies in 2015-2025
10.3.4 The Need for New Business Models?
10.3.5 Developing the Stem Cell Therapy Market
10.3.6 Other Trends and Developments
10.4 Interview with Dr Artur Isaev, General Director, Human Stem Cells Institute, Moscow, Russia
10.4.1 Future Prospects for Cord Blood Stem Cell Banking
10.4.2 Increasing Competition in Stem Cell Banking
10.4.3 Progress with Gemacell and Cryocell
10.4.4 Opportunities in Russia and Other Markets
10.4.5 Challenges for Stem Cell Companies Over 2015-2025
10.4.6 Developing the Stem Cell Therapy Market
10.4.7 Other Trends and Developments
10.5 Interview with Dr Alan Trounson, Emeritus Professor, Monash University, Melbourne, Australia
10.5.1 Improved Funding in the Stem Cells Field
10.5.2 MSCs: Major Potential or Merely a Placeholder?
10.5.3 CIRM Investment Strategies
10.5.4 The Changing Regulatory Environment Worldwide
10.5.5 Key Trends for the Next Five to Ten Years
10.6 Interview with Dr Andras Nagy, Senior Scientist, Samuel Lunenfeld Research Institute, Mount Sinai Hospital
10.6.1 Overview of the Current State of the IPSC Field
10.6.2 Genomic Stability and Other Potential Issues for IPSCs
10.6.3 Potential for Treating and Modelling Diseases with IPSCs
10.6.4 Reprogramming Without Transgenes
10.6.5 Possibilities for Directly-Converted Cells
11. Conclusions
11.1 Stem Cell Technologies and Applications: An Emerging Market
11.2 The Stem Cell Technologies and Applications Market in 2014
11.2.1 Current Leading Stem Cell Technologies and Applications Segments
11.2.2 Leading Regional Markets
11.3 World Stem Cell Technologies and Applications Market Forecast 2015-2025
11.4 Stem Cell Technologies and Applications Late-Stage Pipeline
11.5 The Future of the Stem Cell Technologies and Applications Market
11.5.1 Challenges for the Stem Cells Market
11.5.2 Concluding Remarks
List of Tables
Table 2.1 Potency and Source of Stem Cells
Table 2.2 Germ Layers and Their Associated Types of Cells and Organs, 2014
Table 2.3 Main Types of Stem Cells and Their Properties, 2014
Table 2.4 Stem Cell Donor Terminology, 2014
Table 2.5 NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2014
Table 2.6 Clinical Trial Phases
Table 2.7 Currency Exchange Rates, 2013 and 2014
Table 3.1 Stem Cell Technologies and Applications Market by Region: Revenue ($m), Market Share (%), 2014
Table 3.2 Stem Cell Technologies and Applications Market by Segment: Revenue ($m), Market Share (%), 2014
Table 3.3 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 3.4 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2014-2019
Table 3.5 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2020-2025
Table 3.6 Stem Cell Technologies and Applications Market by Segment: Revenue ($m), Market Share (%), 2019 and 2025
Table 4.1 Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.2 Comparison of Bone Marrow, Peripheral Blood and Cord Blood for HSCT, 2014
Table 4.3 Global HSCT Operations: Estimated Number of Operations by Donor Type, 2012-2014
Table 4.4 European HSCT Operations: Number of Operations by Donor Type, 2003-2012
Table 4.5 Indications with Medicare Coverage for HSCT, 2014
Table 4.6 Malignancies and Other Haematological Diseases Treated with HSCT, 2014
Table 4.7 HSCT-Addressable Cancers: Estimated Incidence in the Major Markets (Number of Cases), CAGR (%), 2012-2024
Table 4.8 FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2014
Table 4.9 Stem Cell Cancer Therapeutics Pipeline, 2014
Table 4.10 Mesoblast: Prochymal Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.1 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.2 Global Cardiovascular Disease Market by Drug Class: Revenue ($bn), 2014
Table 5.3 Projected Global Deaths From Ischaemic Heart Disease and Stroke (millions), % of Total Deaths, Deaths Per 100,000 Population, 2015 and 2030
Table 5.4 Pharmicell: Hearticellgram-AMI Revenue ($m), AGR (%), 2012-2013
Table 5.5 Pharmicell: Hearticellgram-AMI Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.6 Reliance Life Sciences: CardioRel Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.7 Stem Cell Cardiovascular Therapeutics: Phase 2 and Phase 3 Pipeline, 2014
Table 5.8 Stem Cell Cardiovascular Therapeutics: Preclinical and Phase 1 and 1/2 Pipeline, 2014
Table 6.1 Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 6.2 Stem Cell CNS Therapeutics: Phase 2 and 3 Pipeline, 2014
Table 6.3 Stem Cell CNS Therapeutics: Phase 1 and 1/2 Pipeline, 2014
Table 6.4 Stem Cell CNS Therapeutics: Preclinical Pipeline, 2014
Table 7.1 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 7.2 Selected Currently Available Stem Cell Therapeutics for Other Diseases, 2014
Table 7.3 NuVasive: Osteocel Plus Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.4 Orthofix: Trinity Elite and Evolution Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.5 Medipost: Cartistem Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.6 Diseases Other than Cancers to be Treated with HSCT, 2014
Table 7.7 Processes and Mechanism of Bone Repair, 2014
Table 7.8 Stem Cell Therapeutics in Other Diseases: Phase 2 and 3 Pipeline, 2014
Table 7.9 Stem Cell Therapeutics in Other Diseases: Phase 1 and 1/2 Pipeline, 2014
Table 7.10 Stem Cell Therapeutics in Other Diseases: Preclinical Pipeline, 2014
Table 7.11 Selected Genetically Modified Stem Cell Therapies Pipeline, 2014
Table 8.1 Stem Cell Non-Therapeutic Applications Market by Activity: Revenue ($m), Market Share (%), 2014
Table 8.2 Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 8.3 Selected US Stem Cell Banks, 2014
Table 8.4 Selected Non-US Stem Cell Banks, 2014
Table 8.5 Selected Stem Cell Supply and Processing Companies, 2014
Table 8.6 Selected Companies With Involvement in Stem Cell-Based Assays, 2014
Table 8.7 Selected Companies With Other Stem Cell-Related Activities, 2014
Table 9.1 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2014-2025
Table 11.1 Stem Cell Therapy Late-Stage Pipeline, 2014
List of Figures
Figure 1.1 Estimated Numbers of European HSCT Operations, 2003-2014
Figure 1.2 Global Stem Cell Technologies and Applications Market Segmentation Overview, 2014
Figure 2.1 Timeline of Stem Cell Research, 1900-2014
Figure 3.1 Stem Cell Technologies and Applications Market: Market Shares (%) of Therapeutic and Non-Therapeutic Applications, 2014
Figure 3.2 Stem Cell Technologies and Applications Market: Market Share (%) by Region, 2014
Figure 3.3 Stem Cell Technologies and Applications Market by Segment: Market Share (%), 2014
Figure 3.4 Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 3.5 Stem Cell Technologies and Applications Market Forecast: Revenues ($m) by Segment, 2014-2025
Figure 3.6 Stem Cell Technologies and Applications Market: Market Share (%) by Segment, 2019
Figure 3.7 Stem Cell Technologies and Applications Market: Market Share (%) by Segment, 2025
Figure 3.8 Stem Cell Technologies and Applications Market: Drivers and Restraints, 2015-2025
Figure 4.1 Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.2 Global HSCT Operations by Donor Type, 2014
Figure 4.3 European HSCT Operations by Donor Type, 2003-2012
Figure 4.4 HSCT-Addressable Cancers: Estimated Incidence in the Major Markets (Number of Cases), 2012-2024
Figure 4.5 Mesoblast: Prochymal Revenue ($m), AGR (%), 2014-2025
Figure 4.6 Stem Cell Cancer Therapeutics Market: Drivers and Restraints, 2015-2025
Figure 5.1 Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%),2014-2025
Figure 5.2 Global Cardiovascular Disease Market by Drug Class: Market Share (%), 2014
Figure 5.3 Projected Global Deaths From Ischaemic Heart Disease and Stroke (millions), 2015 and 2030
Figure 5.4 Pharmicell: Hearticellgram-AMI Revenue ($m), 2012-2013
Figure 5.5 Pharmicell: Hearticellgram-AMI Revenue ($m), AGR (%), 2014-2025
Figure 5.6 Reliance Life Sciences: CardioRel Revenue ($m), AGR (%), 2014-2025
Figure 5.7 Stem Cell Cardiovascular Therapeutics Market: Drivers and Restraints, 2015-2025
Figure 6.1 Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 6.2 Stem Cell CNS Therapeutics Market: Drivers and Restraints, 2015-2025
Figure 7.1 Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 7.2 NuVasive: Osteocel Plus Revenue ($m), AGR (%), 2014-2025
Figure 7.3 Orthofix: Trinity Elite and Evolution Revenue ($m), AGR (%), 2014-2025
Figure 7.4 Medipost: Cartistem Revenue ($m), AGR (%), 2014-2025
Figure 8.1 Stem Cell Non-Therapeutic Applications Market by Activity: Market Share (%), 2014
Figure 8.2 Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 8.3 Stem Cell Non-Therapeutic Applications Market: Drivers and Restraints, 2015-2025
Figure 9.1 Stem Cell Technologies and Applications Market: Strengths and Weaknesses, 2015-2025
Figure 9.2 Stem Cell Technologies and Applications Market: Opportunities and Threats, 2015-2025
Figure 9.3 Stem Cell Technologies and Applications Market: STEP Analysis, 2015-2025
Figure 9.4 World 65+ Population Forecast: Size (m), AGR (%), 2014-2025
Figure 11.1 Stem Cell Technologies and Applications Market Forecast: Revenues ($m) by Therapeutic and Non-Therapeutic Applications, 2014-2025
3-D Matrix
Adistem
Advanced Cell Technology
Ageless Regenerative Institute
Aldagen
Alder Biopharmaceuticals
Alkems
AllCells
Allergan
Alliancells Bioscience Corporation (subsidiary of Zhongyuan Union Stem Cell Bio-engineering)
AlloCure
Allosource
ALS Association
American Academy of Pediatrics (AAP)
American Board of Cosmetic Surgery
American Board of Otolaryngology/head and Neck Surgery
American College of Surgeons
American CryoStem
American Society of Blood and Marrow Transplantation
Americas Committee for Treatment and Research in Multiple Sclerosis
Americord
Amgen
Amorcyte
AngioCrine Bioscience
Angiotech Pharmaceuticals
Anterogen (subsidiary of Bukwang Pharm Co Ltd)
Antria
apceth
Aristotle University of Thessaloniki
Arteriocyte
Asterias Biotherapeutics (subsidiary of BioTime)
Athersys
Autogenesis
Axiogenesis
Baxter International
BaYi Brain Hospital (China)
Beike Biotechnology
Berkshire Hathaway
Beth Israel Deaconess Medical Center
BioCardia
BioE
BioEden
Biogen Idec
Biogenea-Cellgenea
Bioheart
Biologic Therapies
Biomatrica
Biomet
BioRestorative Therapies
Biotec Services International
BioTime
BioTime Asia (subsidiary of BioTime)
Blackstone Medical (acquired by Orthofix)
bluebird bio
Boston Children's Hospital
BrainStorm Cell Therapeutics
Bukwang Pharm Co Ltd
California Institute of Regenerative Medicine (CIRM)
California Institute of Technology (Caltech)
Calimmune
Cancer Research UK / Cancer Research Technology
Capricor
Cardio3 BioSciences
Cardiogenesis
Carolinas Cord Blood Bank
Casey Eye Institute, Oregon Health and Science University
Cedars-Sinai Heart Institute
Celgene
Celgene Cellular Therapeutics (formerly Anthrogenesis; subsidiary of Celgene)
Cell Cure Neurosciences (subsidiary of BioTime)
Cell Surgical Network
Cell Targeting (assets acquired by BioTime)
Cell Therapy Limited
Cellartis (subsidiary of Takara Bio)
CellCentric
Cellectis
Cellerant Therapeutics
Cellerix (merged with TiGenix)
Cellonis Biotechnologies
CellProthera
CellSeed
Cellular Biomedicine Group
Cellular Dynamics International (CDI)
Center for International Blood and Marrow Transplant Research (CIBMTR)
Centers for Medicare & Medicaid Services (CMS)
Cephalon (part of Teva)
Cesca Therapeutics
CHA Biotech
Cha General Hospital (Seoul, South Korea)
Chicago Medical School
China Cord Blood Corporation
Chinese Academy of Sciences
Cipla
CJ CheilJedang
Cleveland Biolabs
ClinImmune Labs
Cognate BioServices
Consortium of Multiple Sclerosis Centers
Cook General BioTechnology
Cord Blood America
Cord Blood Registry Systems
Cordlife Group
CoreStem
CRISPR Therapeutics
Cryo-Cell International
CryoCord
Cryonix CJSC
Cryo-Save
CryoSite
CXR Biosciences
Cynata Therapeutics (formerly Eco Quest Ltd)
Cytori Therapeutics
Dendreon
Department of Biotechnology (India)
Dong-A Pharmaceuticals Co. (South Korea)
Duke University
Eli Lilly
EpiStem
ES Cell International (subsidiary of BioTime)
ESI BIO (subsidiary of BioTime)
European Group for Blood and Marrow Transplantation (EBMT)
European Haematology Association
European Medicines Agency (EMA)
Fate Therapeutics
FDS Pharma
Fondazione Centro San Raffaele
Fondazione Telethon
Forbion Capital Partners
Forticell Bioscience
Gamida Cell
Gemabank (Human Stem Cells Institute cord blood bank)
Genetrix Group
Genomics Institute, Novartis Research Foundation
Genzyme (part of Sanofi)
Geron Corporation
Gilead Sciences
GlobalStem
Globocan
GMP Unlimited
Grey Innovation
GSK
Hadassah Medical Center
Harvard Apparatus Regenerative Technology
Harvard Business School
Harvard Stem Cell Institute
Harvard University
Health Canada
Human Fertilisation and Embryology Authority (HFEA) (UK)
Human Stem Cells Institute (Russia)
ImmunoCellular Therapeutics
Immunovative Therapies
Insception Biosciences
Institute of Biomedical Research (Japan)
IntelliCell Biosciences
International Society for Stem Cell Research (ISSCR)
International Stem Cell Corporation (ISCO)
International Stemcell Services
Intrexon Corporation
Invivo Therapeutics
IPS Academia Japan
IRCCS San Raffaele Hospital
Israel Stem Cell Society
JCR Pharmaceuticals
Johann Wolfgang Goethe University Hospital
Johnson & Johnson
Karolinska Institute
Kreos Capital
Life Stem Genetics
Lifebank Cryogenics
LifebankUSA
LifeMap Sciences (subsidiary of BioTime)
LifeMap Solutions (owned by Lifemap Sciences)
LifeSouth Community Blood Centers
Lincoln Park Capital
Lonza
Massachusetts General Hospital
Maxcyte
Mayo Clinic
McLean Hospital
MedCell Bioscience
Medical Protective Company
Medicines and Healthcare Products Regulatory Agency (MHRA) (UK)
Medipost
Medistem (formerly Medistem Laboratories; acquired by Intrexon)
Medistem Panama
Medpace Inc.
Medtronic
Merck & Co.
Merck Millipore
Mesoblast
MetaCyte Business Lab
Miltenyi Biotec
Ministry of Economy, Trade and Industry (Japan)
Ministry of Food and Drug Safety (MFDS) (South Korea)
Ministry of Health (China)
Ministry of Science and Technology (China)
Monash University
Mount Sinai Hospital
Musculoskeletal Transplant Foundation
National Dental Pulp Laboratory (subsidiary of New England Cryogenic Center)
NeoStem
NeuralStem
NeuroGeneration
NeuroSearch
New England Cryogenic Center
New York Blood Center
New York Heart Association
Nippon Zoki Pharmaceutical
Northern Therapeutics
Novartis
NsGene
Nuo Therapeutics (formerly Cytomedix)
NuVasive
OncoCyte (subsidiary of BioTime)
Opexa Therapeutics
OrbusNeich
OrthoCyte (subsidiary of BioTime)
Orthofix
Osiris Therapeutics
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmicell (formerly FCB-Pharmicell)
Pharmsynthez
Plasticell
Pluristem
Polyphor
Proneuron Biotechnologies
Q Therapeutics
Queen Mary University of London
Quest Biomedical
Recyte Therapeutics (subsidiary of BioTime)
Regenerative Medicine Institute of Tijuana
Regenerative Sciences
Regenerex
Regenetech
Regeneus
Reliance Life Sciences
ReNeuron
Renovo Neural
RenovoCyte (subsidiary of Cook General BioTechnology)
RepliCel Life Sciences
ReproCELL
RhinoCyte
RIKEN Center for Developmental Biology
Roche
Roslin Cellab
RTI Surgical
RUSNANO
Rutgers University
Samuel Lunenfeld Research Institute
San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET)
SanBio
Saneron CCEL Therapeutics
Sanofi
Sao Paolo University Hospital
Schepens Eye Research Institute
S-Evans Biosciences
Singapore National Eye Centre
Sirna Therapeutics
Skye Orthobiologics
Society for Neuroscience
Spinesmith Partners
SSM Cardinal Glennon Children's Medical Center
St. Louis Cord Blood Bank
Stamina Foundation
Stem Cell Therapeutics
Stemcell Technologies
StemCells
StemCore
StemCyte
Stemedica Cell Technologies
StemGen
Stemina Biomarker Discovery
Stempeutics
SynBio (joint venture)
Takara Bio
TAP Biosystems (Sartorius Stedim Biotech)
Targazyme (formerly America Stem Cell)
Tel Aviv University
Teva
Texas Medical Board
Therapeutic Goods Administration (TGA) (Australia)
Theratechnologies
Tianhe Stem Cell Biotechnologies
TiGenix
Tong Yuan Stem Cell
TrakCel
Translational Biosciences (subsidiary of Medistem Panama)
UHV Technologies
UK Medical Research Council
uniQure
University College London
University of California San Francisco
University of Colorado
University of Heidelberg
University of Kyoto
University of Massachusetts
University of Miami
University of Milan
University of Minnesota
University of Washington
University of Wisconsin
Uppsala University Hospital
US Food and Drug Administration (FDA)
US National Institute of Allergy and Infectious Diseases (NIAID)
US National Institutes of Health (NIH)
US National Marrow Donor Program
US Patent and Trademark Office
Valeant
Vericel Corporation (formerly Aastrom Biosciences)
Vesta Therapeutics
ViaCord
ViaCyte (formerly NovoCell)
ViroMed Laboratories
Vitro Biopharma
WA Optimum Health Care
World Health Organization
Yale University
Yonsei University
Zhongyuan Union Stem Cell Bio-engineering
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
